VivoSeq
Neurology

Juvenile Dermatomyositis

11

Pipeline Programs↗

2

Active Trials↗

6

Companies Involved↗

Juvenile Dermatomyositis is an emerging landscape with 11 programs across 6 companies. The most active players are Chongqing Precision Biotech Co., Ltd, Pfizer, Roche. 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

38/100

Pipeline Velocity

6/100

Mech. Concentration

40/100

Completion Rate

83/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Chongqing Precision Biotech Co., Ltd

2 programs

Phase 1Pfizer logo

Pfizer

1 program

Phase 2Roche logo

Roche

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

8programs
Small molecule450%
Cell therapy225%
Monoclonal antibody113%
Protein / enzyme113%

Modality classified for 100% of 12 pipeline programs.

Analysis

Trial Status

8

clinical trials

Completed5 · 63%
Recruiting2 · 25%
Withdrawn1 · 13%

Clinical Trials

Trial Activity

8 trials

Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis
Recruiting·CChongqing Precision Biotech Co., Ltd·Phase 1·NCT06569472·10 enrolled
Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment of Refractory Juvenile Dermatomyositis (RJDM)
Recruiting·CChongqing Precision Biotech Co., Ltd·Phase 1·NCT06686524·18 enrolled
Absorption of Corticosteroids in Children With Juvenile Dermatomyositis
Completed·NNorthwestern University·Phase 2·NCT00004357·6 enrolled
Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)
Completed·UUniversity of Pittsburgh·Phase 2·NCT00106184·200 enrolled
Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT)
Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT05524311·16 enrolled
Abatacept in Juvenile Dermatomyositis
Completed·GGeorge Washington University·Phase 4·NCT02594735·10 enrolled
Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis
Completed·—·Phase 3·NCT00323960·139 enrolled
Study of Deucravacitinib for Refractory Adults With Dermatomyositis/Juvenile Dermatomyositis
Withdrawn·National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)·Phase 2·NCT07012057

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)